FDA fast-tracks Union Therapeutics drug for rare skin disease
The US health authority has spotted the opportunity address an unmet medical need by expediting the Danish company’s drug candidate for hidradenitis suppurativa.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
Union Therapeutics has had a good regulatory run, and on Tuesday, the US Food and Drug Administration, FDA, awarded another fast-track designation to the Danish biotech company.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Union Therapeutics begins phase IIb trial of eczema tablet
For subscribers
Dupixent might halt "the atopic march," research finds
For subscribers
